research Alopecia Areata. Current situation and perspectives
Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.
Search
for
Sort by
Research
180-210 / 1000+ results research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research A review on laser and light-based therapies for alopecia areata
Laser and light therapies, especially the 308 nm excimer laser, are effective and safe for treating alopecia areata, but more research is needed.
research Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients
Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.
research Correlation between increased total serum IgE levels and clinical features in alopecia areata patients
Higher IgE levels may play a role in alopecia areata, especially in males, children, and severe cases.
research Effect of cannabis use on alopecia areata
Cannabis might help hair regrowth in alopecia areata.
research Comparative characteristics of the effectiveness of drugs for the treatment of alopecia areata in childhood
Betamethasone injections are more effective than Clobetasol for treating alopecia areata in children.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
research Treatment strategies for alopecia
Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research MODERN PERSPECTIVES ON THE PATHOPHYSIOLOGY OF ALOPECIA AREATA (literature review)
Alopecia areata is an autoimmune disease causing hair loss, linked to immune and gut issues, needing more research for better treatments.
research Therapeutic effectiveness in alopecia areatasystematic review and meta-analysis
Minoxidil 5% helps with patchy alopecia areata, but more research is needed.
research Clinical and demographic characteristics associated with nail involvement in alopecia areata: A cross‐sectional study of 197 patients
Younger patients with severe alopecia areata often have nail problems.
research Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata
Contact immunotherapy can improve hair regrowth in alopecia areata patients.
research Alopecia areata. Actualidad y perspectivas
Alopecia areata needs new treatments targeting autoimmune processes due to its emotional impact and variable treatment responses.
research Alopecia areata after mogamulizumab treatment
Mogamulizumab can cause hair loss and skin rashes.
research Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
research Clinical and Molecular Diagnostic Criteria of Congenital Atrichia with Papular Lesions11This paper originally appeared in issue 117:1662–1665, 2001. Following publication the authors indicated that important corrections at page proof were not taken in. To ensure that the paper is published as intended, the editors have decided to reproduce the contents in full.
Congenital atrichia with papular lesions is often misdiagnosed, and new diagnostic criteria can improve accuracy.
research Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Case of alopecia universalis accompanied by minimal change nephrotic syndrome
A possible link exists between minimal change nephrotic syndrome and complete hair loss.
research Treating of resistant cases of alopecia universalis
Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Recovery from Alopecia Universalis after Bilateral Lung Transplantation
A patient regrew hair after a lung transplant using standard post-transplant medication.
research Three hundred and eight nanometer excimer light therapy for alopecia universalis that is resistant to other treatments: A clinical study of 11 patients
308-nm excimer light therapy helped over a third of treatment-resistant alopecia universalis patients regrow most of their hair.
research The PER3 rs772027021 SNP induces pigmentation phenotypes of dyschromatosis universalis hereditaria
The PER3 rs772027021 SNP may cause mild skin pigmentation changes in a new subtype of dyschromatosis universalis hereditaria.
research Bimatoprost in the treatment of eyelash universalis alopecia areata
Bimatoprost helped eyelash growth in nearly half of the patients with a type of eyelash hair loss.
research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report
A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.